Chapter 86 Goldman Sachs in Action

The first phase of Guangjia Technology's human hibernation technology experiment is almost over.

No adverse reactions have been found in the existing samples, which does not mean that there are no adverse reactions, but that the probability is very small, less than one in one hundred thousand.

Because human hibernation technology is a completely new field, American has already obtained specific data from its channels in China, and Goldman Sachs began to make plans after obtaining the data.

They believe that since the adverse reactions are so low, it can be promoted extensively in America.

In the early stages, human experiments can be used as an excuse to conduct large-scale experiments among illegal immigrant groups, which can save experimental costs. The cost of legitimate drug testers is much higher than that of illegal immigrants.

Even if the experimental site is located in India or South Africa, the cost is still very high. This industry is already very regulated, and multinational companies have even stricter requirements. If you are not careful, you will be fined a huge amount.

The Indians are eyeing the situation covetously and are worried about the lack of financial resources.

It’s different with illegal immigration. Even if something happens, it will only be a topic of discussion in the media for two days at most.

Goldman Sachs also has other plans, which is to try to explore whether human hibernation technology is addictive and whether it can extend human life.

The extended life here refers to whether the human body can be put into hibernation continuously, in a mode of being awake for one day and sleeping for three days, so that people can age more slowly than normal people.

Such experiments can only be carried out under the guise of humanistic concern.

"Mr. Chen, in order to promote human hibernation technology into America, we have thought of many ways to lobby the White House.

We have found some possible entry points, but they require the cooperation of light armor technology."

Goldman Sachs is taking action.

Lobbyists in Washington are working hard to persuade senators on Capitol Hill to turn a blind eye to human hibernation technology while mobilizing the power of the country to promote human hibernation technology.

Goldman Sachs executives in Greater China are also taking action to persuade Chen Yuanguang.

"We need a completely new cooperation model. It is feasible for Guangjia Technology to set up branches in Europe, South Africa and Southeast Asia, and Guangjia Technology can obtain most of the profits.

It won't work in North America. Washington is naturally wary of Chinese companies, not to mention that light armor technology involves such sensitive technology as the human brain.

You know, members of Capitol Hill can make up any excuse, and Tik Tok controls what Americans think.

Huawei's equipment may affect security, so won't Guangjia Technology's human hibernation technology also affect security?

In that case, not only would Guangjia Technology be unable to enter the American market, it would not even be able to enter the European market.

We hope that through cooperation, Guangjia Technology can hide behind the scenes, penetrate through layers of equity, package itself as a biopharmaceutical company in the Maple Leaf Country, and cooperate with Arcadia.

Arcadia will eventually conduct clinical trials and equipment sales in North America," said Kara Mangon, formerly the global head of climate strategy at Goldman Sachs and now a senior executive in charge of strategic investment at Goldman Sachs Greater China.

Chen Yuanguang asked: "Why Arcadia, not Merck?"

Kara Mangon's heart trembled. It was beyond her expectation that Chen Yuanguang could mention Merck.

From the outside world's perspective, Goldman Sachs and Pfizer have the best relationship and have long-term cooperation. Goldman Sachs has always recommended Pfizer on various occasions.

In fact, only insiders know that Merck has always been Goldman Sachs' first choice for large-cap pharmaceutical stocks. Goldman Sachs' relationship with Merck is much closer than that with Pfizer. The relationship with Pfizer is just superficial courtesy, and the conflict of interests between the two parties is far less than that with Merck.

As a Chinese, Chen Yuanguang has never worked on Wall Street, so it is very rare for him to dig up information at this level.

Kara Mangon adjusted her mood: "If human hibernation technology is to be rolled out across the United States, the company needs to be of a certain size, and not just any company can do this. And because it involves Chinese technology after all, and the products also come from China, there are risks involved, and Merck is too large.

Arcadia has been deeply engaged in innovative drugs for many years. Its previous innovative drugs were related to mental illness and Alzheimer's disease. Their promotion and clinical trials of human hibernation technology are very suitable. In addition, its market value is just over 20 billion US dollars. Even if this shell is abandoned, the loss is acceptable. "

After listening to this, Chen Yuanguang couldn't help but sigh that Goldman Sachs was too smart and powerful, and could easily find such a suitable white glove to do this.

If it were him, he wouldn't be able to do it no matter how long he spent.

"I see, I need time to think about it.

How do we divide it between us?

Kara Mangon said: "If you are willing to transfer the technology once, you can name the price.

If there is no technology transfer, then the price will be calculated based on equipment purchases.”

China obviously would not agree to technology transfer, "Then we can just purchase equipment.

This matter must be kept secret, and there must not be any trace of this technology or light armor technology on the surface."

The reason why Chen Yuanguang is so cautious is that it is obvious that direct sales have the greatest benefits, and in the equipment sales model, no matter how high the unit price is, the profit is limited.

Direct sales are a continuous cash cow.

Once the cooperation model between Light Armor Technology and American is leaked, other countries and regions will also demand the same cooperation model, which will seriously affect the interests of Light Armor Technology.

Kara Mangon: “Obviously, this exposure has had a much bigger impact on us.

I will help you arrange the intermediary enterprises, operating procedures and so on.

At that time, the bill will be paid to the Mexican branch."

This refers to the profit sources of the Mexican branch, including profits from direct sales of human hibernation in Mexico and sales of equipment in North America.

Chen Yuanguang realized that the Democratic Party and Goldman Sachs were fully confident that Mexico was completely under their control.

"it is good!"

Guangjia Technology can make some profit from this kind of cooperation, but it is less than from direct sales. It is better than nothing.

Moreover, if they did not cooperate with Goldman Sachs, it would definitely have a serious impact on Guangjia Technology's operations in overseas markets, so Chen Yuanguang agreed very readily.

Kara Mangon extended her hand and shook hands with Chen Yuanguang: "It's a pleasure to work with you."

The cold touch made Chen Yuanguang realize that the workplace witch in front of him was actually a femme fatale. He was also very curious about how the human hibernation technology would affect America under the operation of Goldman Sachs.

"When will your company go public?" Lin Qinghua asked.

It's the New Year again. Chen Yuanguang had been in Pengcheng at the end of the year preparing for the establishment of the Guangjia Aerospace R&D Center. He went straight back to Guangzhou as soon as the New Year arrived.

Lin Jia returned to Hangzhou to celebrate the New Year. As soon as he returned, he had to face questions from relatives and friends. They didn't care what you wanted to answer or what you didn't want to answer, they only cared about what they wanted to ask.

"I don't know. It depends on Chen Yuanguang's opinion, and also on how the talks with the institutions and the China Securities Regulatory Commission go. I can't go public just because I want to." Lin Jia said helplessly.

　I will slowly make up for the rest of the past two days. Today is still two chapters with 6k
　　
　
(End of this chapter)